Jacinta Downing v. Abbott Laboratories

48 F.4th 793
CourtCourt of Appeals for the Seventh Circuit
DecidedSeptember 12, 2022
Docket21-2746
StatusPublished
Cited by45 cases

This text of 48 F.4th 793 (Jacinta Downing v. Abbott Laboratories) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jacinta Downing v. Abbott Laboratories, 48 F.4th 793 (7th Cir. 2022).

Opinion

In the

United States Court of Appeals For the Seventh Circuit ____________________ No. 21-2746 JACINTA DOWNING, Plaintiff-Appellant, v.

ABBOTT LABORATORIES and ABBOTT MOLECULAR, INC., Defendants-Appellees. ____________________

Appeal from the United States District Court for the Northern District of Illinois, Eastern Division. No. 1:15-cv-05921 — John J. Tharp, Jr., Judge. ____________________

ARGUED JUNE 3, 2022 — DECIDED SEPTEMBER 12, 2022 ____________________

Before SYKES, Chief Judge, and FLAUM and BRENNAN, Cir- cuit Judges. BRENNAN, Circuit Judge. Jacinta Downing worked for many years as a sales manager and then a sales executive at Abbott Molecular, Inc. Over time, that company faced finan- cial difficulties. The company said that because of reductions in its sales force and Downing’s work performance, it ended her employment. Downing claims the company racially dis- criminated and retaliated against her, so she sued. 2 No. 21-2746

Many of her claims survived summary judgment, but after trial a jury found for Abbott Molecular. On appeal Downing challenges several of the district court’s decisions, including evidentiary rulings, the exclusion of her expert witness, the jury instructions, and the testimony of her former manager, on which she moved for a mistrial. Downing argues that these errors, individually and cumulatively, denied her a fair trial. She also appeals the grant of summary judgment to the com- pany on her disparate-impact claim, for which she contends she had sufficient evidence. We conclude that as to each deci- sion, the district court ruled correctly or did not abuse its dis- cretion, so we affirm. I. Background Our description of the relevant facts comes from the jury trial transcript and other district court records. A. Factual Jacinta (or Jay) Downing, an African-American woman, had many years of sales experience when she was hired in 2002 by Abbott Molecular, Inc., a subsidiary of Abbott Labor- atories. Downing’s first job was Area Sales Manager. Her su- pervisor was Chris Jowett, a white man, who in 2009 arranged for her to be promoted to be one of four Regional Sales Man- agers. Each supervised a team of sales representatives who sold millions of dollars of healthcare products to hospitals, commercial laboratories, and clinics, and who negotiated ser- vice contracts. According to Downing, she “really liked working for” Jo- wett, who was “very inspirational” and mentored her. She considered him a man of great integrity and honesty. In March 2011 Jowett reviewed Downing and gave her an No. 21-2746 3

overall performance rating of “achieved expectations.” Ac- cording to that review, one of her main challenges was fore- casting future business. Downing also fell somewhat short in developing relationships with decisionmakers at key ac- counts, and she was not comfortable with some of Abbott Mo- lecular’s product categories. In 2012, Jowett gave Downing a performance rating of “ex- ceeded expectations,” the highest rating available. He wrote, “Jay is a strong leader for the Abbott Molecular sales organi- zation and can be counted on to deliver results in spite of chal- lenges. I look forward to Jay’s continued success at Abbott Molecular.” Jowett was pleased with Downing’s improve- ment over the previous year, and by giving her the “exceeded expectations” rating Jowett said he was encouraging Down- ing. Shortly after completing that performance review, Jowett accepted a new role at Abbott. Abbott Molecular came under financial pressure in early 2012. Medicare cut its reimbursement rates for a key Abbott product, which significantly impacted the company’s mar- gins. Multiple competitors also entered the market with up- dated versions of products Abbott sold. In response, Abbott changed personnel in the Abbott Molecular division and re- duced its work force. Mark Bridgman, a white man, was transferred from another Abbott division to fill Jowett’s for- mer role in Abbott Molecular. Abbott also created the position of National Sales Director for the U.S. to “coach and guide the sales managers and reps on a day-to-day basis a bit more beyond what [Bridgman] was able to do.” In October 2012, Peter Farmakis, a white man, was hired to fill the role. Farmakis oversaw one man, Mike Kohler 4 No. 21-2746

(who is white), and three women: Jean Gray (who is white), Charlotte Jones (who is African-American), and Downing. Almost immediately, Farmakis had issues with Downing, as well as with some of the other managers who reported to him. Downing had a conflict with a customer, in which she withheld a software key that could have possibly disrupted patient care, in October 2012. Farmakis was displeased, and he instructed Downing not to disrupt patient care going for- ward. Two months later, Farmakis was upset after he learned Downing had unilaterally informed another customer that Abbott would forgive a termination fee of $177,000. By Janu- ary 2013, Farmakis had a list of concerns about Downing’s performance, including oversights in end-of-year sales fore- casting, which impacted other parts of Abbott’s business. Farmakis discussed his concerns about Downing’s perfor- mance with Sarah Longoria, Abbott Molecular’s human re- sources director in February 2013. The next month, Farmakis gave Downing her performance review. Although Downing’s overall rating was “achieved expectations,” Farmakis in- cluded some detailed criticisms of her performance and iden- tified areas for improvement. In July 2013, Farmakis had a conference call with his four direct reports: Kohler, Gray, Jones, and Downing. According to Downing, Farmakis was “shouting and screaming” at the three women, whom he accused of “throwing in the towel.” Downing reported the incident to Abbott’s Employee Rela- tions Department. She relayed her belief that Farmakis was discriminating against her because of her race and gender. About the same time, Gray also complained to Employee Re- lations about Farmakis’s behavior. Gray, Jones, and Downing No. 21-2746 5

discussed their opposition to Farmakis’s management in emails with each other. Abbott investigated these complaints against Farmakis. An Employee Relations specialist sent a climate survey to the four managers who reported to him. In August 2013, Gray, Jones, and Downing gave very negative responses, which fo- cused primarily on Farmakis’s management style. Gray wrote that “[Farmakis is] especially hard on Jay. He embarrasses her and calls her out in calls or emails, part of the unfairness. Her numbers are good so don’t understand why he calls her out, makes her feel stupid, don’t know why he’s doing that to her.” The Employee Relations specialist removed the identify- ing information from the survey responses, deleted some of the comments, and sent them to Longoria. The anonymized feedback was shared with Farmakis, who Bridgman then coached to improve his management style. Throughout 2013, Abbott Molecular’s business continued to falter, resulting in layoffs. In January 2014, Abbott realigned its sales teams. Sales representatives who had pre- viously reported to Downing were assigned to new teams. During the same month, Abbott also placed Downing on a performance improvement plan, the last step before termina- tion. Downing then retained legal counsel and gave notice that she intended to file discrimination claims against the company. Abbott later cut Downing’s stock award in March 2014, which left her unhappy. That fall Downing filed a discrimination charge with the EEOC, which she later amended. Throughout 2014 Abbott’s business had not improved, so the company instituted 6 No. 21-2746

another reduction in force in January 2015. All four Regional Sales Managers, including Downing, lost their jobs when that position was eliminated. Farmakis, the National Sales Direc- tor, was also terminated.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
48 F.4th 793, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jacinta-downing-v-abbott-laboratories-ca7-2022.